Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup
Novo Nordisk just cut the price of its weight-loss drug, Wegovy, by more than half for patients who pay without insurance. Amgen (AMGN) announced this week that it has begun two late-stage clinical trials for its experimental weight-loss drug, MariTide. And Big Pharma is lobbying for a tax break that would have saved…Read more... [...]
Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
How AI tax startup Blue J torched its entire business model for ChatGPT—and became a $300 million company
In the winter of 2022, as the tech world was becoming mesmerized by the sudden, explosive arrival of OpenAI’s ChatGPT, Benjamin Alarie faced a pivotal choice. His legal tech startup, Blue J, had a r [...]
Marble enters the race to bring AI to tax work, armed with $9 million and a free research tool
Marble, a startup building artificial intelligence agents for tax professionals, has raised $9 million in seed funding as the accounting industry grapples with a deepening labor shortage and mounting [...]
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous w [...]
Intuit compressed months of tax code implementation into hours — and built a workflow any regulated-industry team can adapt
When the One Big Beautiful Bill arrived as a 900-page unstructured document — with no standardized schema, no published IRS forms, and a hard shipping deadline — Intuit's TurboTax team had a [...]
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
London-headquartered biotech startup Verdiva has emerged from stealth with a whopping $410mn for a new range of drugs aimed at tackling the obesity epidemic. It’s one of Europe’s largest-ever biot [...]
Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year
Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for the blockbuster drugs Ozempic and Wegovy, the company [...]
Cheaper Wegovy, 23andMe shutters, and RFK Jr. cuts FDA jobs: Pharma news roundup
Novo Nordisk is expanding its cash-only savings program offering its blockbuster weight-loss drug Wegovy for $499 a month at all U.S. pharmacies. 23andMe has filed for Chapter 11 bankruptcy protection [...]
